Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?

Mohammed Alsalmi; Jawad Al-Kassmy; Woojin Kang; Michael Palayew; Philippe Huot

doi:10.1080/14656566.2023.2298345

Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?

Expert Opin Pharmacother. 2024 Jan-Apr;25(1):1-3. doi: 10.1080/14656566.2023.2298345. Epub 2024 Feb 1.

Authors

Mohammed Alsalmi¹, Jawad Al-Kassmy², Woojin Kang³, Michael Palayew², Philippe Huot^{1

3

4}

Affiliations

¹ Movement Disorder Clinic, Division of Neurology, Department of Neurosciences, McGill University Health Centre, Montreal, QC, Canada.
² Royal College of Surgeons in Ireland, School of Medicine, Dublin, Ireland.
³ Neurodegenerative Disease Group, Montreal Neurological Institute-Hospital (The Neuro), Montreal, QC, Canada.
⁴ Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.

PMID: 38116733
DOI: 10.1080/14656566.2023.2298345

No abstract available

Keywords: AV-101; CPL500036; DSP-9632P; JM-010; Parkinson’s disease; Tianqi Pingchan granule; befiradol; buspirone; dyskinesia; ketamine; lenrispodun; levodopa; mesdopetam.

Publication types

Editorial

MeSH terms

Antiparkinson Agents / adverse effects
Dyskinesias* / drug therapy
Humans
Levodopa / adverse effects
Parkinson Disease* / drug therapy

Substances

Levodopa
Antiparkinson Agents